Abdominal obesity or central obesity is medical condition in which
excessive fat has built up around the abdomen and stomach to that it
may have a negative impact on the human health. An individual is
abdominally obese if the size of their waist is more than 90 cm in
males and over 84 cm in females.
Report Overview @
https://www.transparencymarketresearch.com/abdominal-obesity-treatment-market.html
It has been observed that unhealthy lifestyle practice and over
consumption of fast foods are the major causes of abdominal obesity
among population. In terms of geography, North America is the largest
market for abdominal obesity treatment market due to the large base
of obese patients. According to the WHO, the prevalence of obesity
and overweight in the regions of the Americas is the highest followed
by Europe and Eastern Mediterranean regions. Moreover, according to
the Centers for Disease Control and Prevention (CDC), approximately
35% of the adult population of the U.S. is obese.
However, other regions such as South East Asia, Middle East and Latin
America are some of the potential market where introduction of
effective novel therapies might boosts up the overall market growth
of abdominal obesity treatment. Due to the significant rise in
obesity and rising awareness among population, these regions are
expected to be the lucrative market venture for abdominal obesity
treatment.
The primary factors driving the growth of this market are increasing
base of population suffering from obesity and increasing levels of
awareness amongst weight conscious population. Moreover, development
of safe and effective therapeutics for the treatment of abdominal
obesity might contribute to the growth of the abdominal obesity
treatment market. For instance, a novel anti-obesity therapeutic,
Bupropion/zonisamide (planned brand name Empatic) is an
investigational combination therapeutic for obesity treatment. The
drug is currently at phase IIB clinical trial and is being developed
by California, the U.S. based, Orexigen Therapeutics, Inc.
Download Report Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=33908
The drug has successfully demonstrated positive trial results
compared to placebo and monotherapies. Thus, the introduction of
promising drugs in this market is likely to boosts the overall
abdominal obesity treatment market due to the high success and
effectiveness rate of the potential molecules. Furthermore,
increasing government support for developing novel therapies along
with high research and development initiatives on the development of
personalized medicines are also expected to fuel the growth of this
market.
In addition, technological breakthrough such as minimally invasive
surgical devices and increased focus on retaining superior quality of
life are some of the factors that might contribute to the growth of
this market. However, rise in overall healthcare expenditure and side
effects of the anti-obesity drugs are some of the market-restraining
factors that might hinder the growth of the abdominal obesity
treatment market in the near future.
Currently, the abdominal obesity treatment market is a highly
attractive and promising market venture due to the high incidence
rate of obesity among population. Various pharmaceutical and
biotechnology companies are trying to develop novel therapeutics,
which can be used for the treatment of abdominal obesity. Some of the
companies involved with the development and commercialization of
therapeutic products for treating abdominal obesity are Arena
Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline
plc, Novo Nordisk A/S, Orexigen Therapeutics, Inc., Upsher-Smith
Laboratories Inc. and Vivus, Inc., amongst others.
Pre-Book Full Report @
https://www.transparencymarketresearch.com/checkout.php?rep_id=33908<ype=S
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment